Medtronic plc has announced the launch of InPen™ integrated with real-time Guardian Connect™ CGM data. InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI).

This integrated system now provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes in one view. Rather than switching between apps, users have the ability to see all their information in real-time, in one view — making it easier to make smarter dosing decisions to manage their sugar levels.

The integration of real-time CGM data into the smart insulin pen app is a result of the addition of Companion Medical's InPen to the Medtronic portfolio, as of September 2020. The acquisition enables Medtronic to serve more people — regardless of how they prefer their insulin to be delivered — and offers a unique and expansive ecosystem of support across their diabetes journey.

"We're strongly committed to delivering solutions that make life easier for people living with diabetes. We're pleased to build on the success of InPen with added real-time glucose data which provides a complete picture for users as they look to give themselves the right dose of insulin at the right time," said Sean Salmon, Executive Vice President and President, Diabetes Business, Medtronic.

The InPen app will continue to display information from other currently compatible CGM systems on a three-hour delay.